Hyperfractionated irradiation and concurrent cisplatin in brain stem tumors: a Pediatric Oncology Group pilot study (9139).
A phase I Pediatric Oncology Group Study was performed combining 7,020 cGy hyperfractionated irradiation (117 cGy twice daily separated by 6 h) with increasing concurrent doses of cisplatin given with the intent of radiosensitization as treatment for children with newly diagnosed brain stem tumors. Cisplatin was infused over 120 h on weeks 1, 3, and 5 during a 6-week radiotherapy course. The following cisplatin dose levels were studied: (1) 50 mg/m2/120 h, (2) 75 mg/m2/120 h and (3) 100 mg/m2/120 h. Sixteen of 17 children completed therapy. One child expired after 2 days of treatment secondary to massive intratumoral hemorrhage. At cisplatin dose level 3 (100 mg/m2/120 h), grade 2-4 myelosuppression was encountered in 3 of 5 evaluable patients. Otherwise, no other excessive toxicities, including renal and ototoxicity, were noted.
Kadota
R P
RP
Children's Hospital and Health Center, San Diego, Calif.
Mandell
L R
LR
Fontanesi
J
J
Kovnar
E H
EH
Krischer
J
J
Kun
L E
LE
Friedman
H S
HS
D000293:Adolescent; D000328:Adult; D001932:Brain Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D001933:Brain Stem / Q000473:pathology / Q000528:radiation effects*; D002648:Child; D002675:Child, Preschool; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016371:Cranial Irradiation; D004305:Dose-Response Relationship, Drug; D005609:Free Radicals; D006311:Hearing Disorders / Q000139:chemically induced; D006801:Humans; D007275:Injections, Intravenous; D010865:Pilot Projects; D011379:Prognosis; D016896:Treatment Outcome
D005609:Free Radicals; D002945:Cisplatin